4.5 Review

The Hospital Readmissions Reduction Program Nationwide Perspectives and Recommendations: A JACC: Heart Failure Position Paper

期刊

JACC-HEART FAILURE
卷 8, 期 1, 页码 1-11

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.jchf.2019.07.012

关键词

30-day readmission; heart failure; HRRP; Medicare

资金

  1. Patient-Centered Outcomes Research Institute
  2. National Institutes of Health
  3. American Heart Association
  4. National Heart, Lung, and Blood Institute [K23HL109177-03]
  5. AstraZeneca
  6. Bayer
  7. Luitpold
  8. GlaxoSmithKline
  9. Merck
  10. Novartis
  11. Portola Pharmaceuticals
  12. Verily
  13. ResMed
  14. Bristol-Myers Squibb

向作者/读者索取更多资源

The mandatory federal pay-for-performance Hospital Readmissions Reduction Program (HRRP) was created to decrease 30-day hospital readmissions by instituting accountability and stimulating quality care and coordination, particularly during care transitions. The HRRP has changed the landscape of hospital readmissions and reimbursement within the United States by imposing substantial Medicare payment penalties on hospitals with higher-than-expected readmission rates. However, the HRRP has been controversial since its inception, particularly in the field of heart failure. Proponents argue that it has reduced national readmission rates, in part by raising awareness and investment in mechanisms to better assist patients during discharge and transitions; opponents contend that it unfairly penalizes hospitals for issues beyond their control, has unintended negative consequences due to incentivizing readmission over survival, that it encourages gaming the system, was not tested before implementation, and that it does not specify how hospitals can improve their performance. This paper incorporates the diverse, nuanced, and sometimes divergent interpretations presented during a multifaceted expert clinician discussion regarding the HRRP and heart failure; in cases in which consensus opinions were achieved, they are presented, including regarding potential new iterations of the HRRP for the future. Potential improvements include more comprehensive incorporation of outcomes into the HRRP measure and better risk adjustment to improve equality and fairness. (C) 2020 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据